Filana Therapeutics Inc. Common Stock (FLNA)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I have made my career buying understandable businesses with durable competitive advantages, honest accounting, and a margin of safety. Filana Therapeutics does not fit that mold. It is a clinical-stage biotechnology company with 17 employees, no revenue, and a lead drug, simufilam, in Phase 3 for Alzheimer's disease. The filed numbers show persistent losses: net loss of $97.2 million in FY2023, $24.3 million in FY2024, and $91.0 million in FY2025. In fiscal Q1 2026, the quarter ended 2026-03-31, it lost another $10.3 million. As of the 2026-10-13 close, FairStock calculates a market cap of $35.7 million, a P/E of -0.85, a P/B of 0.56, an ROE of -55.78%, an ROCE of -7.14%, and a trailing free cash flow yield of -82.0%, with TTM free cash flow of -$29.3 million. Its Piotroski F-Score is 1/9 and Altman Z-Score is -5.90. The computed Peter Lynch category is none, because it has lost money in each of the last four years. A sub-book valuation can look tempting, but asset value here is largely being consumed by trials, not generating cash. The moat, if any, would come only from successful clinical data and regulatory protection. Until then, this is a binary research bet, not a Graham-style bargain.

In plain English: Filana Therapeutics is a tiny clinical-stage biotech trying to develop an Alzheimer's drug and a blood test. It has no revenue and has posted large losses, including a $91.0 million loss in fiscal 2025 and a $10.3 million loss in fiscal Q1 2026. The stock is very low at $0.74, but because the company does not make money and spends cash, it looks speculative rather than clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer